Highly specific SGLT2 inhibitors have been developed and approved by the FDA to treat type 2 diabetes mellitus (T2DM), and they lower blood glucose by excreting glucose into the urine (see [3]). The gene discussed is SLC5A2; the disease is diabetes mellitus.